NASDAQ:RLAY Relay Therapeutics (RLAY) Stock Price, News & Analysis → America could fall from this event (From Porter & Company) (Ad) Free RLAY Stock Alerts $6.42 0.00 (0.00%) (As of 05/13/2024 ET) Add Compare Share Share Today's Range$6.36▼$6.7650-Day Range$5.90▼$10.3252-Week Range$5.70▼$13.32Volume1.17 million shsAverage Volume1.14 million shsMarket Capitalization$852.19 millionP/E RatioN/ADividend YieldN/APrice Target$22.20 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Relay Therapeutics alerts: Email Address Relay Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside245.8% Upside$22.20 Price TargetShort InterestBearish8.69% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.28Based on 17 Articles This WeekInsider TradingSelling Shares$27,965 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.83) to ($2.78) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.95 out of 5 starsMedical Sector1188th out of 2,771 stocksBiological Products, Except Diagnostic Industry160th out of 462 stocks 4.5 Analyst's Opinion Consensus RatingRelay Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageRelay Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Relay Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.69% of the outstanding shares of Relay Therapeutics have been sold short.Short Interest Ratio / Days to CoverRelay Therapeutics has a short interest ratio ("days to cover") of 9.4.Change versus previous monthShort interest in Relay Therapeutics has recently increased by 7.86%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldRelay Therapeutics does not currently pay a dividend.Dividend GrowthRelay Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RLAY. Previous Next 2.4 News and Social Media Coverage News SentimentRelay Therapeutics has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 17 news articles for Relay Therapeutics this week, compared to 2 articles on an average week.Search Interest4 people have searched for RLAY on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Relay Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -38% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Relay Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $27,965.00 in company stock.Percentage Held by InsidersOnly 4.32% of the stock of Relay Therapeutics is held by insiders.Percentage Held by Institutions96.98% of the stock of Relay Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Relay Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Relay Therapeutics are expected to grow in the coming year, from ($2.83) to ($2.78) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Relay Therapeutics is -2.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Relay Therapeutics is -2.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRelay Therapeutics has a P/B Ratio of 1.09. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Relay Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceElon Musk’s Next Move Will Disrupt AI ForeverA revolutionary venture that is set to get rolled out by May 16. One well-connected Silicon Valley VC has uncovered a way for anybody to claim a stake in "Elon Musk's AI 2.0" with as little as $100.Get all the information here. About Relay Therapeutics Stock (NASDAQ:RLAY)Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Read More RLAY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RLAY Stock News HeadlinesApril 30, 2024 | insidertrades.comRelay Therapeutics, Inc. (NASDAQ:RLAY) CFO Thomas Catinazzo Sells 1,695 SharesMay 13 at 8:30 AM | globenewswire.comRelay Therapeutics to Host New Program and Platform Event on June 6, 2024May 13 at 5:38 AM | americanbankingnews.comRelay Therapeutics (NASDAQ:RLAY) Lifted to Overweight at BarclaysMay 12 at 3:30 AM | americanbankingnews.comRelay Therapeutics (NASDAQ:RLAY) Shares Gap Up to $6.31May 10, 2024 | msn.comRelay Therapeutics upgraded by Barclays ahead of data readoutMay 10, 2024 | msn.comBarclays Upgrades Relay Therapeutics (RLAY)May 9, 2024 | americanbankingnews.comLeerink Partnrs Research Analysts Lower Earnings Estimates for Relay Therapeutics, Inc. (NASDAQ:RLAY)May 9, 2024 | americanbankingnews.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Receives $24.00 Consensus PT from AnalystsMay 8, 2024 | markets.businessinsider.comOptimistic Buy Rating for Relay Therapeutics: Pipeline Progress and Financial Stability Drive Analyst ConfidenceMay 8, 2024 | americanbankingnews.comRelay Therapeutics (NASDAQ:RLAY) Rating Reiterated by JMP SecuritiesMay 8, 2024 | americanbankingnews.comRelay Therapeutics (NASDAQ:RLAY) Rating Reiterated by OppenheimerMay 4, 2024 | finance.yahoo.comRelay Therapeutics First Quarter 2024 Earnings: Beats ExpectationsMay 4, 2024 | americanbankingnews.comRelay Therapeutics (NASDAQ:RLAY) Shares Gap Up After Strong EarningsMay 2, 2024 | finance.yahoo.comRelay Therapeutics Outperforms Revenue Expectations in Q1 2024May 2, 2024 | investorplace.comRLAY Stock Earnings: Relay Therapeutics Beats EPS, Beats Revenue for Q1 2024May 2, 2024 | globenewswire.comRelay Therapeutics Reports First Quarter 2024 Financial Results and Corporate HighlightsApril 25, 2024 | globenewswire.comRelay Therapeutics to Announce First Quarter 2024 Financial Results and Corporate Highlights on May 2, 2024April 11, 2024 | globenewswire.comRelay Therapeutics to Participate in Upcoming Investor ConferencesMarch 19, 2024 | markets.businessinsider.comStrong Buy Rating for Relay Therapeutics Amid Pipeline Progress and Strategic DirectionMarch 16, 2024 | finance.yahoo.comRLAY Apr 2024 7.500 callMarch 16, 2024 | finance.yahoo.comRLAY Apr 2024 7.500 putMarch 15, 2024 | investorplace.com3 Precision Medicine Stocks That Could Benefit From the Industry's RiseMarch 13, 2024 | seekingalpha.comRelay Therapeutics: Platform More Important Than ProgramsFebruary 26, 2024 | globenewswire.comRelay Therapeutics to Participate in Three Upcoming Investor ConferencesFebruary 26, 2024 | markets.businessinsider.comRelay Therapeutics: Strong Buy on Improved Financials and Promising Future MilestonesSee More Headlines Receive RLAY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Relay Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today5/13/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:RLAY CUSIPN/A CIK1812364 Webwww.relaytx.com Phone617-370-8837FaxN/AEmployees323Year FoundedN/APrice Target and Rating Average Stock Price Target$22.20 High Stock Price Target$30.00 Low Stock Price Target$15.00 Potential Upside/Downside+245.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-341,970,000.00 Net Margins-1,263.49% Pretax Margin-931.61% Return on Equity-42.66% Return on Assets-37.04% Debt Debt-to-Equity RatioN/A Current Ratio20.73 Quick Ratio20.73 Sales & Book Value Annual Sales$25.55 million Price / Sales33.35 Cash FlowN/A Price / Cash FlowN/A Book Value$5.90 per share Price / Book1.09Miscellaneous Outstanding Shares132,740,000Free Float127,008,000Market Cap$852.19 million OptionableOptionable Beta1.68 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Alexis A. Borisy A.M. (Age 52)Co-Founder & Independent Chairman Comp: $92.5kDr. Sanjiv K. Patel M.A. (Age 50)M.B.A., M.D., MBBS, CEO, President & Director Comp: $1.08MDr. Mark Murcko Ph.D. (Age 64)Co-Founder & Director Comp: $60kMr. Thomas Catinazzo (Age 47)Chief Financial Officer Comp: $663.99kMr. Brian R. Adams J.D. (Age 50)Chief Legal Officer & Secretary Comp: $627.72kMr. Peter RahmerChief Corporate Development OfficerDr. Donald A. Bergstrom M.D. (Age 52)Ph.D., President of Research & Development Comp: $1.37MDr. Deborah Palestrant M.B.A.Ph.D., Vice President of Corporate Development & StrategyMr. Jim Watters Ph.D.Chief Scientific Officer of Late ResearchDr. Beni B. Wolf M.D.Ph.D., Chief Medical Officer & Head of Precision MedicineMore ExecutivesKey CompetitorsImmaticsNASDAQ:IMTXMesoblastNASDAQ:MESOREGENXBIONASDAQ:RGNXCARGO TherapeuticsNASDAQ:CRGXAutolus TherapeuticsNASDAQ:AUTLView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 1,165,282 shares on 5/10/2024Ownership: 8.901%Russell Investments Group Ltd.Bought 65,484 shares on 5/8/2024Ownership: 0.136%ProShare Advisors LLCBought 3,394 shares on 5/8/2024Ownership: 0.020%Susquehanna Portfolio Strategies LLCSold 1,647 shares on 5/7/2024Ownership: 0.157%Swiss National BankBought 7,100 shares on 5/7/2024Ownership: 0.123%View All Insider TransactionsView All Institutional Transactions RLAY Stock Analysis - Frequently Asked Questions Should I buy or sell Relay Therapeutics stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Relay Therapeutics in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RLAY shares. View RLAY analyst ratings or view top-rated stocks. What is Relay Therapeutics' stock price target for 2024? 7 Wall Street research analysts have issued 1-year target prices for Relay Therapeutics' stock. Their RLAY share price targets range from $15.00 to $30.00. On average, they predict the company's share price to reach $22.20 in the next year. This suggests a possible upside of 245.8% from the stock's current price. View analysts price targets for RLAY or view top-rated stocks among Wall Street analysts. How have RLAY shares performed in 2024? Relay Therapeutics' stock was trading at $11.01 on January 1st, 2024. Since then, RLAY shares have decreased by 41.7% and is now trading at $6.42. View the best growth stocks for 2024 here. When is Relay Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our RLAY earnings forecast. How were Relay Therapeutics' earnings last quarter? Relay Therapeutics, Inc. (NASDAQ:RLAY) issued its quarterly earnings results on Thursday, May, 2nd. The company reported ($0.62) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.70) by $0.08. The business had revenue of $10.01 million for the quarter, compared to analysts' expectations of $0.12 million. Relay Therapeutics had a negative net margin of 1,263.49% and a negative trailing twelve-month return on equity of 42.66%. Relay Therapeutics's revenue for the quarter was up 4327.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.78) earnings per share. What ETFs hold Relay Therapeutics' stock? ETFs with the largest weight of Relay Therapeutics (NASDAQ:RLAY) stock in their portfolio include Tema Oncology ETF (CANC).TrueShares Technology, AI & Deep Learning ETF (LRNZ). What other stocks do shareholders of Relay Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Relay Therapeutics investors own include Beyond Meat (BYND), CureVac (CVAC), QuidelOrtho (QDEL), Teladoc Health (TDOC), Tesla (TSLA), Datadog (DDOG), DraftKings (DKNG), eHealth (EHTH), GoHealth (GOCO) and Intel (INTC). When did Relay Therapeutics IPO? Relay Therapeutics (RLAY) raised $250 million in an initial public offering (IPO) on Thursday, July 16th 2020. The company issued 14,700,000 shares at $16.00-$18.00 per share. J.P. Morgan, Goldman Sachs, Cowen and Guggenheim Securities served as the underwriters for the IPO. Who are Relay Therapeutics' major shareholders? Relay Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (8.90%), Baillie Gifford & Co. (0.27%), Susquehanna Portfolio Strategies LLC (0.16%), Russell Investments Group Ltd. (0.14%), Swiss National Bank (0.12%) and Congress Asset Management Co. MA (0.11%). Insiders that own company stock include Andy Porter, Brian Adams, Donald A Bergstrom, Mark Murcko, Peter Rahmer, Sanjiv Patel and Thomas Catinazzo. View institutional ownership trends. How do I buy shares of Relay Therapeutics? Shares of RLAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RLAY) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsElon’s New Device is About to Shock the WorldInvestorPlaceTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaCharles Payne Demystifies OptionsUnstoppable ProsperityForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressNo experience to confident trader, meet my student…Wealth Builders InstituteThe only AI company you should be looking atBehind the MarketsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Relay Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.